News Archive
Please note that the contents in this webpage are current as of the date of the announcement and the information including but not limited to the product availability, specification, prices, contacts, are subject to change without prior notice.
- Category
- Date
-
-
2026.03.26Press ReleaseAnnouncement of New Management Structure
-
2026.03.25InformationAnnouncement of Website Renewal
-
2026.02.04Press ReleasePeptiDream, PDRadiopharma and Curium Group Enroll First Patient to Registrational Clinical Trial of 177Lu-PSMA-I&T for Prostate Cancer in Japan
-
2026.01.26Press ReleasePDRadiopharma Launches Solar Power Generation at Chiba Site – Advancing ESG Management through the Use of Renewable Energy –
-
2025.12.22Press ReleasePeptiDream Announces FDA Approval of IND Applications for Phase 1 Clinical Trials of 225Ac-PD-32766 and 64Cu-PD-32766 in Patients with Kidney Cancer(PeptiDream Inc.)
-
2025.12.11Press ReleaseApproval of Clinical Research Protocol for 64Cu-PD-29875, a Claudin 18.2-Targeting Radiopharmaceutical, in Patients with Gastric Cancer(PeptiDream Inc.)
-
2025.12.05Press ReleaseR&D Briefing Materials (December 5, 2025)(PeptiDream Inc.)
-
2025.11.25Press ReleasePeptiDream Submits IND Applications for Phase 1 Clinical Trials of 225Ac-PD-32766 and 64Cu-PD-32766 in Patients with Kidney Cancer(PeptiDream Inc.)
-
2025.11.19InformationUpcoming Conference Presentation at RSNA2025
-
2025.11.06InformationPDRadiopharma to Present and Exhibit at the 65th Annual Scientific Meeting of the Japanese Society of Nuclear Medicine and the 45th Annual Meeting of the Japanese Society of Nuclear Medicine Technology
-
2025.10.15Press ReleasePeptiDream, PDRadiopharma and Curium Group Enroll First Patient to Registrational Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan
-
2025.10.01InformationUpcoming Conference Presentation at EANM’25(PeptiDream Inc.)
-
2025.09.25Press ReleaseLaunch of “onti dandori” – A Scheduling Module for the “onti” System for Nuclear Medicine Exposure Dose Management
-
2025.09.19Press ReleaseBridgea DISPENSER Now Equipped with Liquid Collection Function — Enhancing Operational Efficiency and Safety in Radiopharmaceutical Preparation
-
2025.09.19Press ReleasePDRadiopharma Receives Approval for Expanded Indication of Raiatt MIBG-I131 for Neuroblastoma
-
2025.07.08Press ReleasePeptiDream Announces Submission of IND Application for Clinical Trials of 177Lu-PSMA-I&T and 64Cu-PSMA-I&T
-
2025.06.25Press ReleasePDRadiopharma Inc. Announcement of the Releases of “AMYfollow TM”:Software for Supporting Longitudinal Reporting of Amyloid PET Imaging
-
2025.05.20Press ReleasePDRadiopharma Submits Partial Change Application for Additional Indication of Raiatt MIBG-I131 for Neuroblastoma
-
2025.04.07InformationPress ReleaseFurther Enhancements Added to the “onti” Medical Isotope Exposure Dose Management System
-
2025.03.31InformationPDRadiopharma Host Joint Seminar at The 84th Annual Meeting of the Japanese Society, and Exhibit at the International Technical Exhibition of Medical Imaging 2025
-
2025.03.28Press ReleaseNew Radiopharmaceuticals for Renal Cell Carcinoma -Assessing the potential of PD-32766 as a PET diagnostic and raising expectations for novel diagnostic and therapeutic agents in nuclear medicine-(National Cancer Center/PeptiDream Inc.)
-
2025.03.28InformationAnnouncement of New Management Structure
-
2025.03.21InformationPeptiDream Featured in a Video Produced by the Prime Minister’s Office of Japan(PeptiDream Inc.)
-
2025.03.17Press ReleaseNew Functionality Added to the “onti” Medical Isotope Exposure Dose Management System
-
2025.02.17InformationFinancial Results Presentation (Fiscal Year Ending December 2024)(PeptiDream Inc.)
-
2025.02.14Press ReleaseConsolidated Financial Results for the Fiscal Year Ended December 31, 2024 [IFRS](PeptiDream Inc.)
-
2025.02.13Press ReleasePeptiDream Awarded Prime Status in ISS ESG Corporate Rating for the First Time(PeptiDream Inc.)
-
2025.01.16Press Release“Bridgea GATEWAY” and “onti” Pass the IHE-J2024 Connectathon Interoperability Test
-
2025.01.10Press ReleaseLinqMed Announces Series B Funding First close(PeptiDream Inc.)
-
2024.12.27Press ReleaseRegulatory Approval for Tauvid® ,a PET Imaging Agent
-
2024.12.17InformationPress ReleasePeptiDream to Construct New Radiotherapeutic/Radiodiagnostic Manufacturing Facility at Kazusa Akademia Park, Chiba
-
2024.12.12Press ReleasePDRadiopharma Inc. Releases ‘Report Creation Support Software’ for Amyloid PET scans.
-
2024.12.10Press ReleasePeptiDream Announces Upcoming Presentation of Ph0 Human Imaging Study Results for 64Cu-PD-32766, CA9-Targeting PD-32766 Program at ASCO Genitourinary Cancers Symposium
-
2024.12.06Press ReleasePDRadiopharma announces listing of Techne® Pyrophosphate Injection on Japan National Health Insurance Drug Price List and Upcoming Market Launch
-
2024.12.05Press ReleaseNorthStar Medical Radioisotopes and PDRadiopharma Announce Research and Development Agreement, Master Isotope Supply Agreement for Ac-225 and Contract Manufacturing and Master Services Agreement
-
2024.11.20Press ReleaseExpansion of Insurance Coverage of AMYViD®, a PET Imaging Agent for Detecting Beta Amyloid
-
2024.11.14InformationPress ReleaseOur Strategic Partner, Curium Announces ECLIPSE Trial has Met Primary Endpoint, Demonstrating a Statistically Significant and Clinically Meaningful Benefit for Patients With PSMA-Positive Metastatic Castration Resistant Prostate Cancer(Curiumu)
-
2024.11.06Press ReleasePeptiDream Announces Upcoming Presentations, and PDRadiopharma to Exhibit at the 64th Annual Scientific Meeting of the Japanese Society of Nuclear Medicine and the 44th Annual Meeting of the Japanese Society of Nuclear Medicine Technology
-
2024.11.05Press ReleasePDRadiopharma Inc. Receives “Controlled Medical Device” Certification for Brain Imaging Analysis Program “AMYclz® Neuro”
-
2024.10.23Press ReleasePeptiDream Announces Upcoming Presentation of CA9-Targeting PD-32766 Program at the Annual Meeting of the Japan Society of Urologic Oncology(PeptiDream Inc.)
-
2024.10.01Press ReleasePDRadiopharma, a PeptiDream Company, and Curium Announce Strategic Partnership for the Development and Commercialization of 177Lu-PSMA-I&T and 64Cu-PSMA-I&T in Japan
-
2024.10.01InformationAnnouncement of New Management Structure
-
2024.09.30Press ReleaseLaunch of Medical DX (Digital Transformation) Solutions “Bridgea TIMER Guide” and “onti-d”
-
2024.09.03Press ReleaseApproval of Partial Change to the Indication of AMYViD®,a PET Imaging Agent for Detecting Beta Amyloid
-
2024.07.01Press ReleaseDr. Masato Murakami Appointed as President and Representative Director of PDRadiopharma(PeptiDream Inc.)
-
2024.07.01Press ReleaseAnnouncement of New Management Structure
-
2024.05.22Press ReleaseAnnouncement of listing on the NHI Drug Price Standard of AMYViD®, a PET Imaging Agent for Detecting Beta Amyloid
-
2023.12.22Press ReleaseApproval of Partial Change to the Indication of MyoMIBG® -I 123 Injection for Cardiac Scintigraphy for Patients with Parkinson’s Disease and Dementia with Lewy Bodies
-
2023.12.22Press ReleasePeptiDream and LinqMed Announce Strategic Partnership for the Development and Commercialization of 64Cu-ATSM in Japan(PeptiDream Inc.)
-
2023.12.20Press ReleaseApproval of Insurance Coverage of AMYViD®, a PET Imaging Agent for Detecting Beta Amyloid
-
2023.10.31Press ReleaseAcquisition of Assets for Radiopharmaceutical Data Solutions
-
2023.08.31InformationApproval of partial change to the indication of AMYViD®, a PET imaging agent for detecting beta amyloid
-